BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/25/2024 8:28:59 AM | Browse: 288 | Download: 981
 |
Received |
|
2023-11-06 09:24 |
|
Peer-Review Started |
|
2023-11-06 09:24 |
|
First Decision by Editorial Office Director |
|
2023-11-16 02:12 |
|
Return for Revision |
|
2023-11-16 02:12 |
|
Revised |
|
2023-11-22 00:32 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-01-12 02:42 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-01-12 07:45 |
|
Articles in Press |
|
2024-01-12 07:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-18 05:13 |
|
Publish the Manuscript Online |
|
2024-01-25 08:28 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jing-Hao Zhou, Qi-Jun Yi, Ming-Yan Li, Yan Xu, Qi Dong, Cong-Ying Wang and Hai-Yan Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Science and Technology Innovation Development Project of Tai’an |
2021NS160 |
| the Medical and Health Science and Technology Development Plan of Shandong Province |
202102010647 |
|
| Corresponding Author |
Hai-Yan Liu, MD, Doctor, Doctor, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, No. 706 Taishan Street, Tai’an 271000, Shandong Province, China. fylhy1998@163.com |
| Key Words |
Inetetamab; Gastric cancer; Human epidermal growth factor receptor-2 protein; Tegafur; Case report |
| Core Tip |
In this paper, we present a case involving a patient with human epidermal growth factor receptor-2 (HER2)-positive gastric cancer who was received oxaliplatin combined with tegafur as the first-line treatment post surgery. The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma. He received inetetamab, an innovative domestically developed anti-HER2 monoclonal antibody, combined with tegafur chemotherapy as the second-line treatment. Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition. This is significant because We provided a practical reference case for HER2-positive gastric cancer patients who was received inetetamab that is an innovative domestically developed anti-HER2 monoclonal antibody, which may help to provide survival benefits to some extent. |
| Publish Date |
2024-01-25 08:28 |
| Citation |
Zhou JH, Yi QJ, Li MY, Xu Y, Dong Q, Wang CY, Liu HY. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report. World J Clin Cases 2024; 12(4): 820-827 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i4/820.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i4.820 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
